Frank Bedu-Addo - 15 Jun 2021 Form 4 Insider Report for PDS Biotechnology Corp (PDSB)

Role
President/CEO, Director
Signature
/s/ Frank Bedu-Addo
Issuer symbol
PDSB
Transactions as of
15 Jun 2021
Net transactions value
-$1.58
Form type
4
Filing time
17 Jun 2021, 19:26:07 UTC
Next filing
20 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PDSB Common Stock Options Exercise $349,353 +53,174 +8.6% $6.57 673,681 15 Jun 2021 Direct F1
transaction PDSB Common Stock Tax liability $349,355 -27,166 -4% $12.86 646,515 15 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PDSB Stock Option (Right to Buy) Options Exercise $0 -53,174 -100% $0.000000* 0 15 Jun 2021 Common Stock 53,174 $6.57 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 15, 2021, Mr. Bedu-Addo made a net exercise of 53,174 stock options, resulting in his acquisition of 26,008 common shares of the Issuer. The transaction was made pursuant to an exception to a lock-up agreement between Mr. Bedu Addo and Cantor Fitzgerald & Co.in connection with a public offering of common shares by the Issuer which closed on June 17, 2021.
F2 The Stock Option is fully vested in accordance with its terms.